Table 3 |
|||
|
Adverse events associated with FLV and FLV+TJ-43 treatment. |
|||
| FLV |
FLV+TJ-43 |
||
|
|
|||
| Adverse events |
Number (%) of patients reporting event |
||
|
|
|||
| GI symptoms |
|||
| Nausea |
9 (36) |
3 (12) |
* |
| Anorexia |
3 (12) |
3 (12) |
|
| Abdominal fullness |
1 (4) |
0 (0) |
|
| Constipation |
1 (4) |
0 (0) |
|
| Diarrhea |
1 (4) |
0 (0) |
|
| Feel discomfort |
3 (12) |
2 (8) |
|
| Feel irritable |
1 (4) |
0 (0) |
|
| Difficulty in urinating |
1 (4) |
0 (0) |
|
| General fatigue |
1 (4) |
0 (0) |
|
| Tremor |
0 (0) |
1 (4) |
|
|
|
|||
| /25 |
/25 |
||
|
|
|||
|
FLV = fluvoxamine; TJ-43 = Rikkunshito; GI:gastrointestinal. * p < 0.05 by Fisher exact probability test. |
|||
|
Oka et al. BioPsychoSocial Medicine 2007 1:21 doi:10.1186/1751-0759-1-21 |
|||
